Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

LOS ANGELES, July 16, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...